HKMPF - Hikma resumes launch of generic Advair Diskus

Hikma Pharmaceuticals (HKMPF) has resumed the launch of its generic version of GlaxoSmithKline's blockbuster asthma treatment Advair Diskus in the United States.The launch follows US FDA approval of an amendment Hikma submitted to its Abbreviated New Drug Application ((ANDA)) in January 2021.The amendment reflected enhanced packaging controls to meet new industry standards adopted since the initial submission of its ANDA.

For further details see:

Hikma resumes launch of generic Advair Diskus